US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
CA2295971C
(en)
*
|
1997-07-11 |
2011-02-08 |
THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Pseudomonas exotoxin a-like chimeric immunogens
|
US6809184B1
(en)
*
|
1997-12-01 |
2004-10-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
CA2369433A1
(en)
*
|
1999-02-26 |
2000-08-31 |
Pacific Northwest Research Institute |
Methods and compositions for diagnosing carcinomas
|
US6770445B1
(en)
*
|
1999-02-26 |
2004-08-03 |
Pacific Northwest Research Institute |
Methods and compositions for diagnosing carcinomas
|
US7745159B2
(en)
*
|
1999-02-26 |
2010-06-29 |
Nathalie B Scholler |
Methods and compositions for diagnosing carcinomas
|
DK1180123T3
(da)
*
|
1999-05-27 |
2008-10-13 |
Us Gov Health & Human Serv |
Immunkonjugater, der har höj bindingsaffinitet
|
GB9924351D0
(en)
|
1999-10-14 |
1999-12-15 |
Brennan Frank |
Immunomodulation methods and compositions
|
US6987024B1
(en)
*
|
2000-04-10 |
2006-01-17 |
Raven Biotechnologies, Inc. |
Human ovarian mesothelial cells and methods of isolation and uses thereof
|
AU2002338446A1
(en)
*
|
2001-01-23 |
2002-11-05 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
PT2371854E
(pt)
|
2001-03-09 |
2014-08-25 |
Jackson H M Found Military Med |
Indução da imunidade tumoral por variantes da proteína de ligação ao folato
|
WO2004006837A2
(en)
*
|
2002-07-12 |
2004-01-22 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US7695725B2
(en)
*
|
2003-02-06 |
2010-04-13 |
Aduro Biotech |
Modified free-living microbes, vaccine compositions and methods of use thereof
|
KR101192652B1
(ko)
*
|
2003-02-06 |
2012-10-19 |
앤저 테라퓨틱스 인코퍼레이티드 |
비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
|
MXPA05008340A
(es)
*
|
2003-02-06 |
2006-03-13 |
Cerus Corp |
Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos.
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
JP2007525971A
(ja)
*
|
2003-08-05 |
2007-09-13 |
モルフォテック、インク. |
癌に関連する変異体細胞表面分子
|
US7399793B2
(en)
*
|
2003-10-31 |
2008-07-15 |
Basf Corporation |
Coating composition curable with ultraviolet radiation
|
SG10201701737XA
(en)
|
2003-11-06 |
2017-04-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US7842289B2
(en)
|
2003-12-24 |
2010-11-30 |
Aduro Biotech |
Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
|
WO2005072341A2
(en)
*
|
2004-01-21 |
2005-08-11 |
Fujirebio America, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
|
US20060014221A1
(en)
*
|
2004-01-21 |
2006-01-19 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
WO2006099141A2
(en)
|
2005-03-10 |
2006-09-21 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
AU2006241099B2
(en)
|
2005-04-22 |
2012-04-19 |
Eisai, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
ES2532942T3
(es)
|
2006-03-01 |
2015-04-06 |
Aduro Biotech |
Listeria obtenida por ingeniería genética y métodos de uso de la misma
|
US20070207171A1
(en)
*
|
2006-03-01 |
2007-09-06 |
Cerus Corporation |
Engineered listeria and methods of use thereof
|
US7935804B2
(en)
*
|
2006-03-01 |
2011-05-03 |
Aduro Biotech |
Engineered Listeria and methods of use thereof
|
WO2008105814A2
(en)
*
|
2006-08-22 |
2008-09-04 |
Los Alamos National Security, Llc |
Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
|
CA2685308A1
(en)
*
|
2007-04-27 |
2009-01-29 |
Dow Global Technologies Inc. |
Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
JP2009028871A
(ja)
|
2007-07-30 |
2009-02-12 |
Denso Wave Inc |
ロボット制御装置
|
PL2195017T3
(pl)
|
2007-10-01 |
2015-03-31 |
Bristol Myers Squibb Co |
Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
|
US9023351B2
(en)
*
|
2007-11-26 |
2015-05-05 |
Bayer Intellectual Property Gmbh |
Anti-mesothelin antibodies and uses thereof
|
WO2009099728A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
US8357783B2
(en)
*
|
2008-03-27 |
2013-01-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human anti-mesothelin monoclonal antibodies
|
US8785134B2
(en)
*
|
2008-11-10 |
2014-07-22 |
The Mitre Corporation |
Glycoprotein vesicles and their methods of use
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
ES2544805T3
(es)
|
2009-09-11 |
2015-09-04 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida
|
WO2011051350A1
(en)
*
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
KR101878889B1
(ko)
|
2011-04-20 |
2018-07-16 |
메사 바이오테크, 인크. |
핵산의 왕복 증폭 반응
|
CN103648525B
(zh)
|
2011-05-06 |
2016-08-24 |
由卫生与公共服务部部长代表的美国政府 |
靶向间皮素的重组免疫毒素
|
KR20140054140A
(ko)
*
|
2011-07-27 |
2014-05-08 |
베일러 리서치 인스티튜트 |
췌장암에 대한 수지상 세포(dc) - 백신 치료요법
|
US9127081B2
(en)
|
2012-05-10 |
2015-09-08 |
Washington University |
Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
EP2888282B1
(en)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
CA2885761C
(en)
|
2012-09-27 |
2021-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
WO2016196506A1
(en)
|
2015-05-29 |
2016-12-08 |
Galena Biopharma, Inc. |
PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
ES2944597T3
(es)
|
2015-12-30 |
2023-06-22 |
Novartis Ag |
Terapias con células efectoras inmunitarias de eficacia mejorada
|
PT3405212T
(pt)
|
2016-01-19 |
2020-08-25 |
Pfizer |
Vacinas para o cancro
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
MA45169A
(fr)
|
2016-05-31 |
2019-04-10 |
Sellas Life Sciences Group Inc |
Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
CN111683962A
(zh)
|
2017-11-10 |
2020-09-18 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|